First-In-Class Claudin-3 Antibody
ABN501
Pan-Carcinoma Target Drug
First-In-Class Claudin-3 Antibody ABN501
Summary
ABN501 is a First-in-class human monoclonal antibody that targets claudin 3 (CLDN3) with exceptional specificity and robust binding capabilities.
Claudin proteins play vital roles in cellular anchoring, signal transduction, and growth regulation by forming tight junctions between cell membranes. While normally hidden within healthy cell tight junctions, these proteins undergo structural changes during cell transformation into cancerous forms, leading to disrupted tight junctions and uncontrolled cell growth, a hallmark of tumor development. Consequently, claudin proteins become exposed in the tumor microenvironment, serving as biomarkers for cancer cells.
Claudin 3 (CLDN3) is a recognized solid tumor marker, often overexpressed in various solid tumors and associated with poor prognosis. Its distinct expression pattern makes it an appealing target for anti-cancer therapy. However, developing antibodies specific to CLDN3 among the diverse claudin family members (24 species in the human body) has been challenging. Additionally, screening for CLDN3 antibodies has proven difficult.
ABN501 stands as a pioneering monoclonal antibody, meticulously crafted to selectively target Claudin 3 (CLDN3) with exceptional precision and binding affinity. ABION has developed ABN501 utilizing its proprietary library. In vitro and in vivo studies have demonstrated ABN501’s remarkable antibody-dependent cytotoxicity (ADCC) activity against Claudin 3 (CLDN3)-positive tumors, effectively eliminating cancer cells. Preclinical testing in animals is slated for 2023.
Mechanism of Action
ABN501
Antibody drug designed to target Claudin 3, inhibiting cancer cells through antibody-dependent cytotoxicity (ADCC) or other platform technologies.
Claudin Proteins in Cancer Progression
Claudin proteins are essential components of tight junctions, contributing to cellular functions like adhesion, signal transduction, and growth regulation. In healthy cells, they are discreetly located within cell membranes. During cancer progression, these proteins undergo alterations, disrupting tight junctions in mutated cancer cells. This disruption allows uncontrolled cell growth, characteristic of tumorigenesis. Consequently, claudin proteins become exposed in the tumor microenvironment, serving as cancer cell biomarkers.
Targeting Claudin 3
Among the 24 members of the claudin protein family, Claudin 3 stands out as a marker for solid tumors, showing widespread presence across various types and correlating with patient prognosis. However, designing antigens to target Claudin 3 presents challenges due to homology among family members and limited exposed regions.
ABN501: Specificity and Efficacy
ABN501 is a pioneering monoclonal antibody with exceptional specificity and robust binding affinity for Claudin 3. Extensive studies have confirmed its ability to induce ADCC against cancer cells, effectively eliminating them. We envision ABN501’s development as a therapeutic agent for various cancer types, leveraging platform technologies like Antibody-drug conjugates (ADC) and bispecific antibodies (BsAb).
Research & Development
Development phase
ABN501
First-In-Class Claudin 3 Antibody Pan-Carcinoma Target Drug
ABN501 is a First-In-Class targeting Claudin 3 (CLDN3) monoclonal antibody with high specificity and strong binding affinity
Platform Technology
“ABN501 is a highly targetable antibody suitable for a variety of platform technologies.”
“ABION is currently exploring several platform technologies to apply ABN501.”
